KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Halozyme Therapeutics (HALO) Cost of Revenue (2016 - 2025)

Historic Cost of Revenue for Halozyme Therapeutics (HALO) over the last 17 years, with Q3 2025 value amounting to $55.2 million.

  • Halozyme Therapeutics' Cost of Revenue rose 1176.71% to $55.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $192.1 million, marking a year-over-year increase of 1320.23%. This contributed to the annual value of $159.4 million for FY2024, which is 1712.61% down from last year.
  • According to the latest figures from Q3 2025, Halozyme Therapeutics' Cost of Revenue is $55.2 million, which was up 1176.71% from $46.4 million recorded in Q2 2025.
  • Halozyme Therapeutics' 5-year Cost of Revenue high stood at $55.2 million for Q3 2025, and its period low was $15.9 million during Q1 2022.
  • Its 5-year average for Cost of Revenue is $38.0 million, with a median of $42.1 million in 2024.
  • In the last 5 years, Halozyme Therapeutics' Cost of Revenue skyrocketed by 30101.05% in 2021 and then plummeted by 2089.67% in 2024.
  • Quarter analysis of 5 years shows Halozyme Therapeutics' Cost of Revenue stood at $21.6 million in 2021, then soared by 95.12% to $42.1 million in 2022, then increased by 24.16% to $52.3 million in 2023, then dropped by 19.59% to $42.1 million in 2024, then skyrocketed by 31.36% to $55.2 million in 2025.
  • Its Cost of Revenue stands at $55.2 million for Q3 2025, versus $46.4 million for Q2 2025 and $48.4 million for Q1 2025.